Prost-Data, which is doing business as OURLab, has 18 phlebotomy sites throughout the US and an experienced national sales force calling primarily on urologists.

Under the purchase, OURLab will provide OPKO with a commercial platform to support the near-term US commercial launch of OURLab’s panel of kallikrein biomarkers and associated algorithm (4Kscore) for the detection of prostate cancer.

Several studies have shown that the use of the 4Kscore may reduce the number of unnecessary prostate biopsies by 50% or more as well as avoid the frequent complications of pain, bleeding, and infection.

OPKO chairman and chief executive officer Phillip Frost said, "We look forward to working together with OURLab’s talented personnel to support the U.S. launch of the important 4Kscore prostate test."